Literature DB >> 20887883

The challenge of non-motor symptoms in Parkinson's disease.

K Ray Chaudhuri1, Per Odin.   

Abstract

The non-motor symptoms (NMS) of Parkinson's disease (PD) are often poorly recognized and inadequately treated in contrast to motor symptoms and a modern holistic approach to treatment of PD should, therefore, include recognition and assessment of NMS. Certain aspects of the NMS complex of PD can be improved with currently available treatments, both dopaminergic and non-dopaminergic, but other features may be more refractory illustrating the importance of research into more effective drug therapies for the future. The American Academy of Neurology has recently published the first task force guidelines in relation to treatment of NMS of PD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20887883     DOI: 10.1016/S0079-6123(10)84017-8

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  53 in total

Review 1.  Premotor Diagnosis of Parkinson's Disease.

Authors:  Heinz Reichmann
Journal:  Neurosci Bull       Date:  2017-08-03       Impact factor: 5.203

Review 2.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

Review 3.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

4.  Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease versus health care professionals: a concept mapping study.

Authors:  Catharina Sjödahl Hammarlund; Maria H Nilsson; Markus Idvall; Scott R Rosas; Peter Hagell
Journal:  Qual Life Res       Date:  2014-01-04       Impact factor: 4.147

Review 5.  Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model.

Authors:  L David Willison; Takashi Kudo; Dawn H Loh; Dika Kuljis; Christopher S Colwell
Journal:  Exp Neurol       Date:  2013-01-24       Impact factor: 5.330

6.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

7.  Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.

Authors:  Andrzej Dekundy; Flora Mela; Martine Hofmann; Wojciech Danysz
Journal:  J Neural Transm (Vienna)       Date:  2014-10-16       Impact factor: 3.575

Review 8.  Synaptic protein alterations in Parkinson's disease.

Authors:  Ilse S Pienaar; David Burn; Christopher Morris; David Dexter
Journal:  Mol Neurobiol       Date:  2011-12-29       Impact factor: 5.590

9.  Human LRRK2 G2019S mutation represses post-synaptic protein PSD95 and causes cognitive impairment in transgenic mice.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Heather L Melrose; Thomas Mosley; Jun Ming Wang
Journal:  Neurobiol Learn Mem       Date:  2017-05-06       Impact factor: 2.877

Review 10.  α-Synuclein and nonhuman primate models of Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neurosci Methods       Date:  2015-08-03       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.